Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. - Wikidata - wikimedia - TriplyDB

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

http://www.wikidata.org/entity/Q34617956

about

Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer Medication-induced osteoporosis: screening and treatment strategies Sex steroid actions in male bone Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Update on medications with adverse skeletal effects Contemporary therapeutic approaches targeting bone complications in prostate cancer A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.Estrogens and prostate cancer: etiology, mediators, prevention, and management.Androgens and estrogens in benign prostatic hyperplasia: past, present and future.Biochemical bone turnover markers and osteoporosis in older men: where are we?Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.An update on androgen deprivation therapy for prostate cancer.Androgen deprivation therapy toxicity and management for men receiving radiation therapy Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Skeletal complications of ADT: disease burden and treatment options.Optimal bone health management strategies in patients with prostate cancer Current management of prostate cancer: dilemmas and trials Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.Management of cancer treatment-induced bone loss.Selective estrogen receptor modulators for BPH: new factors on the ground.Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advan Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.The pharmacotherapy of male hypogonadism besides androgens.Antiresorptive therapy in the management of cancer treatment-induced bone loss.Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.

P2860

Q24597422-EB713229-C897-4C4D-92AB-FADAFC5A952D Q27021268-CC55C43A-AF91-4CF6-A677-E8254729C2B9 Q27024138-B9D39DFD-D716-4E45-9761-BC8850AD06DF Q34023510-7C0D8D97-2196-4282-9E6A-903FA81284CA Q34389358-4BB2F1FD-6565-4C7D-ACF7-C9CBC9BC1F65 Q34437537-50BEB251-F783-43C1-BC01-7B2953C5497D Q34543980-7E17B708-31D3-4631-888B-29D579F7DDF1 Q34748485-FBD367AC-9128-4080-B9BA-6A77AB463516 Q34960778-FFC09FF7-0B68-4EFD-9F8C-C3EE7FDB194B Q35145672-B13BE72C-F9D0-4793-B3B6-3D16D1259E29 Q35196710-20D39948-A831-4537-B4FF-B65D81266871 Q35231660-2B597B42-97A6-4BFC-B542-B82F13A01BB2 Q35636173-0F99D470-9901-4BF0-AC02-5F65F736E29F Q35774987-B7E7F18C-0C83-4767-B4AA-5EB2D83451D5 Q35942134-1E499DFA-132D-4817-AF57-68ACB7B6946D Q36187103-2FAFB866-489F-4501-9BF8-E35D889BA106 Q36289952-AB5ED256-F2ED-4928-AABC-54E3FA150F99 Q36530136-0D691455-ECA3-416F-B88B-743F23B533E4 Q36900752-3CCAB404-1415-4EA6-8791-2CE569A9A374 Q36900784-199FC495-734F-416E-951A-926947726D45 Q36910469-BC33269C-100C-4229-82D2-91C90A96F98E Q37074106-DEBBB2F6-A9CD-489D-8911-E7C6117CB0C5 Q37080734-7E957A51-68C8-4D5B-9ACB-20F3D190CC3F Q37102535-8E8DAEC4-0941-42CF-A766-C11159D7BC84 Q37135281-E5B21FE8-48F2-4CF7-B70E-3F90714FA59D Q37231394-471356FC-59BA-41C2-AD2A-27A7491FA9A3 Q37987236-0693FDE9-FF85-4912-8A6D-984CA39DFC6B Q38016531-6A34C18F-481C-4C8D-BD7D-9ABBBCB4B4EC Q38090917-053BE48D-162D-48C5-B3B2-9A9F10737933 Q38115066-8A164212-FF64-49F3-B2DA-5777DA245652 Q38186795-0945D6A2-DF24-4F3A-86A8-AEC8C7006A26 Q38207463-B1F1BEC6-2E94-4C03-A86C-C449977A6FCC Q38252425-97E56959-CCA8-453F-BAAE-1B41C523FFB1 Q38293550-B82F8132-4BE1-491F-8E96-A10682FE23F2 Q38313112-4209D788-9488-4B0F-BCB8-73625BDC9414 Q38612952-1E970C81-2CF9-42BA-99C3-BCA76F0D0F29 Q39815205-46DCC4A5-2C32-493A-8597-F98C692021BF Q43552073-8DB004FE-24F2-4B46-AC46-AA45DED22BEE Q45748150-FED08A8D-101A-444E-83A7-2CF35845AF9E Q45977053-CEDB1C7B-1FA8-439E-98DD-F5FF733F87CF

P2860

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

http://www.wikidata.org/entity/Q34617956

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@ast

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@en

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@nl

type

label

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@ast

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@en

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@nl

prefLabel

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@ast

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@en

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@nl

P1433

Q34617956-E4489E06-ECB9-4C29-A4B3-3E919752D393

P1476

Q34617956-EC7B4792-4536-4D2E-844B-B4F39451F36C

P2093

Q34617956-06CCF87D-F2C8-44D7-B722-3139157E8924

Q34617956-0ABA9A8D-9987-4BDC-BB35-E0FC97345798

Q34617956-0DDD0871-238E-495C-B21F-A7A7E766D94D

Q34617956-26B17AD4-DF14-4B76-A5A6-FC41CF35BA68

Q34617956-2D06940A-C079-4849-B32D-302BEEB64188

Q34617956-3ABFA12F-6DC5-4D76-9C41-2EBB564CF93C

Q34617956-6D527AD0-D7CC-4CA4-98FA-8AFC923622CB

Q34617956-B24FF4FB-C7CD-4906-BB85-49B1C7A8AE91

P2860

Q34617956-1B9CDE43-74ED-4BD1-A06E-CCC226A10608

Q34617956-27DEB3ED-5356-41BC-8BFF-A24B93C653DF

Q34617956-2BFC022E-71D4-4E46-894D-09AD50CC589B

Q34617956-34757AE6-E781-4A01-8FD9-79C37CF97941

Q34617956-405612D0-7321-42BB-9E9F-56810786C729

Q34617956-5A62E430-0A30-4D32-81B3-34CC2D19495B

Q34617956-660BD3A4-1C4A-4A5E-83AB-5AC548805CCD

Q34617956-69FA2A46-EFF1-4D28-A992-BCF8FC9FF2C2

Q34617956-6D2888F3-AA10-40BE-AFEF-18CA0DE0F5B4

Q34617956-707A5678-9D2D-47CC-8A98-B4596FC188AB

P304

Q34617956-A3EC3574-7DE6-4EFC-AB0C-BFE27EE9271B

P31

Q34617956-DEBBB528-98B1-4A29-962F-C9C785FD3836

P356

Q34617956-E965ECBA-3A50-4337-9612-91C7B82169F6

P407

Q34617956-E6EDBDBC-7AD3-4A2F-8925-F9256EB704CD

P433

Q34617956-02BCCD1F-2A93-4AC0-B682-5278382DCEBD

P478

Q34617956-52D91FBC-3008-4EEB-B7B8-96C3488A3480

P577

Q34617956-1062B489-C17E-4867-9B93-A6CBFA128A00

P5875

Q34617956-85581752-5B49-4A06-BB80-29A42A840D7E

P698

Q34617956-A89C4DF4-EEC7-4A23-8415-0AFACAF7830A

P932

Q34617956-77448ADB-7B12-4993-86D5-BF627A5C942E

P356

J.JURO.2010.06.022

P1433

The Journal of Urology

P1476

Toremifene to reduce fracture ...... n therapy for prostate cancer.

@en

P2093

Domingo Rodriguez

http://www.w3.org/2001/XMLSchema#string

K Gary Barnette

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Michael L Hancock

http://www.w3.org/2001/XMLSchema#string

Mitchell S Steiner

http://www.w3.org/2001/XMLSchema#string

Paul R Sieber

http://www.w3.org/2001/XMLSchema#string

Ronald A Morton

http://www.w3.org/2001/XMLSchema#string

S Bruce Malkowicz

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic complications of androgen deprivation therapy for prostate cancer

Cancer statistics, 2008

Statistical aspects of the analysis of data from retrospective studies of disease

The structural basis of bone fragility in men.

The protective effects of estrogen on the cardiovascular system.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Clinical practice. Osteoporosis in men.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Androgen deprivation therapy for prostate cancer.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

P304

1316-1321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2010.06.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45720280

http://www.w3.org/2001/XMLSchema#string

P698

20723926

http://www.w3.org/2001/XMLSchema#string

P932

3047407

http://www.w3.org/2001/XMLSchema#string